Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NEJM Commentary Rekindles Debate on Communicating CER

July 18, 2013

A commentary published on July 18 in the New England Journal of Medicine is rekindling the debate about comparative effectiveness research (CER) and the pharmaceutical industry’s ability to communicate health information.

Tufts Medical Center economist Peter Neumann, ScD, who authored the commentary, suggests that Section 114 of the Food and Drug Administration Modernization Act of 1997 be “extended to allow drug companies to promote comparative effectiveness research to health plans and other payers. The law would retain its prohibition against such promotions directly to doctors or patients.”

Dr. Neumann’s paper continues the discussion of this issue that kicked off last year with a conference hosted by the National Pharmaceutical Council, a series of articles in Health Affairs, and the federal circuit court of appeals decision on US v. Caronia.

So what does this mean, and why does this debate matter? As NPC has explained before,

To understand industry’s challenge, it is important to recognize two key issues. First, the type of research used by the Food and Drug Administration (FDA) to make drug approval and labeling decisions is more stringent than the information that can be used by other health care decision makers. Second, FDA regulates the type of research that can be discussed by industry in most forums, but not by other stakeholders.

For a new drug to gain FDA approval, a company must provide “substantial evidence” of effectiveness, a standard under which “at least two major clinical trials are required for product approval, although one trial with supporting evidence is sufficient in limited circumstances.” This “substantial evidence” forms the basis for the drug’s labeling, and manufacturers face stiff fines and penalties if they go beyond the labeling claims when marketing or discussing the use of a product outside limited venues recognized to constitute non-promotional scientific exchange.

Although these clinical trials are considered the “gold standard” in research, most of the millions of dollars in CER that will be funded by PCORI will be derived from observational studies, data pulled from claims and payer databases, literature reviews and other public resources, none of which is considered acceptable for approval purposes by the FDA. With an increasing number of payers, academics and government agencies turning to observational methods of conducting CER, the trend leaves industry out of the conversation.

FDA officials have made statements acknowledging industry’s right to dispute unsupported CER evidence as long as the communication is not promotional in nature and reflects the patients, endpoints, and uses specific to the drug’s labeling. With CER studies examining a variety of off-label outcomes and being published in a range of venues outside of scientific journals, the role companies may have in the conversation is significantly reduced.

In a worst-case scenario, a payer could share an inadequate study about off-label use of a drug with its network of health care providers and patients. The results, which have not been subjected to any external oversight or transparency in the research protocol or analysis plan, would likely shape patients’ and providers’ views of the drugs involved and contribute to decision-making. Relying on such an inadequate study could lead to poor patient outcomes and rising costs. Even if the company that produces the drug spots the misleading information, existing communications rules potentially prevent the company from sharing insights on the study’s results and limitations with doctors and patients.

This unequal ability to communicate harms the very people who stand to benefit most from CER findings – the patients and health care providers facing medical decisions. The current communications environment increases the risk that useful details will be withheld or misleading information will go unchallenged. Decision-makers deserve to hear all viewpoints and weigh each source’s potential biases for themselves.

Given the potential penalties that would be incurred for violating the rules, however, companies will be hesitant to participate in open discourse about CER without clear guidance from the FDA. To open communication channels, the FDA will need to articulate standards that encourage dialogue and information-sharing.
Blog Post

CER Tweets of the Week (April 7-11, 2014)

Collaboration was a popular topic among comparative effectiveness research (CER) stakeholders on Twitter this week. They tweeted about the National...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
Blog Post

CER Tweets of the Week (March 31- April 4, 2014)

This week, health care stakeholders on Twitter highlighted the many activities and sessions at the Academy of Managed Care Pharmacy’s (AMCP) 26th...
Blog Post

4/8 Webinar on CER Collaborative: Tools You Can Use

The CER Collaborative--a group formed by the Academy of Managed Care Pharmacy (AMCP), the International Society for Pharmacoeconomics and Outcomes...
Press Release

CER Collaborative Improving Health Outcomes Through New Comparative Evidence Tools

(Washington, DC, March 24, 2014)—Three peer-reviewed articles published in Value in Health offer important guidance to aid formulary decision-makers...
Press Release

NPC, Quintiles Study Tests Tools to Evaluate Quality of Observational Research in Comparative Effectiveness Studies

(Washington, DC, February 25, 2014)—With the growing demand for information about comparative effectiveness and questions about the quality of...
Press Release

NPC, UMD Study: Factors That Cause Different Treatment Responses Are Not Well Understood or Studied

Washington, DC, November 4, 2013—Although researchers and health care providers widely recognize that individuals with stage IV prostate cancer react...
Press Release

National Pharmaceutical Council Statement on Appointment of PCORI Board Chair

Washington, DC, September 19, 2013—The National Pharmaceutical Council (NPC) today released the following statement regarding the Government...
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
Commentary and Testimony Page

Living Up to Its Name? The Role of Patient-Centered Research

Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...
YouTube Videos

Webinar: CER Collaborative: Tools You Can Use

Collaborative members hosted a webinar explaining how to use the tools they developed to create greater uniformity and transparency when evaluating...
YouTube Videos

Leveraging Real-World Data and Analytics in the Device Industry

Thomas Abbott, PhD, head, health care informatics at Johnson & Johnson, Medical Devices and Diagnostics, talks about the impact of big data and...
YouTube Videos

IMEDS: Sentinel and OMOP Programs

Jane Reese-Coulbourne, MS, ChE, executive director of the Reagan-Udall Foundation, talks about the Food and Drug Administration's Sentinel Initiative...
YouTube Videos

Big Data: Its Evolving Use and Challenges

William Crown, PhD, chief scientific officer at Optum Labs, discusses how the use and nature of big data in health care has been evolving in recent...
Blog Post

CER Tweets of the Week (April 7-11, 2014)

Collaboration was a popular topic among comparative effectiveness research (CER) stakeholders on Twitter this week. They tweeted about the National...
Blog Post

CER Tweets of the Week (March 31- April 4, 2014)

This week, health care stakeholders on Twitter highlighted the many activities and sessions at the Academy of Managed Care Pharmacy’s (AMCP) 26th...
Blog Post

4/8 Webinar on CER Collaborative: Tools You Can Use

The CER Collaborative--a group formed by the Academy of Managed Care Pharmacy (AMCP), the International Society for Pharmacoeconomics and Outcomes...
Blog Post

CER Collaborative Rolls Out New Resources to Aid Formulary Decision-Making

A newly published series of peer-reviewed articles developed by the CER Collaborative will help formulary decision-makers more effectively evaluate...

Research

  •  
  • 1 of 12
  • >

Commentary & Testimony